Shares of HCW Biologics Inc. (NASDAQ:HCWB – Get Free Report) rose 0.3% on Thursday . The company traded as high as $0.41 and last traded at $0.39. Approximately 290,430 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 11,194,245 shares. The stock had previously closed at $0.39.
HCW Biologics Stock Performance
The stock’s fifty day moving average is $0.39 and its two-hundred day moving average is $0.47. The firm has a market cap of $17.37 million, a price-to-earnings ratio of -0.39 and a beta of 0.81.
About HCW Biologics
HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.
See Also
- Five stocks we like better than HCW Biologics
- Best Stocks Under $5.00
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- DuPont’s Electronics Spinoff: The Start of Something Big
- How to Short a Stock in 5 Easy StepsÂ
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
